Search

Corvus Pharmaceuticals Inc

Fermé

15.15 0.66

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.96

Max

15.4

Chiffres clés

By Trading Economics

Revenu

-4.3M

-18M

BPA

-0.19

Employés

37

EBITDA

-5.3M

-17M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+109.97% upside

Dividendes

By Acuity

Prochains Résultats

3 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

32M

1.2B

Ouverture précédente

14.49

Clôture précédente

15.15

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 août 2026, 23:56 UTC

News

Molson Coors Beverage Co shares advanced in after-market hours to $43.20, following Q2 revenues of $3.10 billion that met analyst expectations.

13 août 2026, 23:56 UTC

GitLab Inc. shares are trading lower in after-market hours, despite an earlier rebound from session lows. No specific news was identified.

13 août 2026, 23:56 UTC

Pegasystems Inc. shares are lower in after-market trading, with no specific news identified. The broader market reacts to rising initial jobless claims.

13 août 2026, 23:56 UTC

Zebra Technologies shares are trading higher in after-market hours, maintaining strength above its 20-day moving average and near the upper end of its one-month range.

13 août 2026, 23:56 UTC

Correlated Moves

T Rowe Price Group Inc shares are lower in after-market trading, extending a trend of declines over the past three sessions amid broader market weakness.

13 août 2026, 23:56 UTC

iShares TIPS Bond ETF traded roughly flat during after-market hours. The asset remains near the lower end of its one-month trading range.

13 août 2026, 23:56 UTC

Cherry Hill Mortgage Investment Corp is trading lower in after-market hours, declining from earlier gains despite remaining above its 20-day moving average.

13 août 2026, 23:56 UTC

Toast Inc shares are lower in after-market trading. No specific company news was identified to explain this price movement.

13 août 2026, 23:56 UTC

Correlated Moves

Skyworks Solutions Inc shares declined in after-market trading, influenced by broader market movements and rising initial jobless claims indicating potential labor market softness.

13 août 2026, 23:56 UTC

Shares of Camtek Ltd are trading higher in after-market hours, remaining above their 20-day moving average despite routine performance during the regular session.

13 août 2026, 23:56 UTC

NetApp Inc. shares are higher in after-market trading, remaining above their 20-day moving average amid broader market dynamics and rising initial jobless claims.

13 août 2026, 23:56 UTC

Correlated Moves

TPG Inc shares declined in after-market trading, settling lower after earlier gains. The drop aligns with a slight decrease in the Russell 2000 Index.

13 août 2026, 23:56 UTC

News
Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

13 août 2026, 23:56 UTC

Correlated Moves
Macro News
ETF Constituents

iShares MSCI South Korea ETF gains in after-market trading, reflecting KOSPI's surge amid positive sentiment around interest rates and U.S. stock performance.

13 août 2026, 23:52 UTC

Kura Oncology Inc is trading higher in after-market hours, reflecting broader market optimism following recent economic data and a stable producer price index.

13 août 2026, 23:51 UTC

Tyler Technologies Inc shares are higher in after-market trading, reflecting strong performance since Thursday's close, despite no specific news identified to explain the movement.

13 août 2026, 23:51 UTC

Clean Energy Fuels Corp shares are lower in after-market hours, reversing earlier gains amid broader market sentiment influenced by recent economic data.

13 août 2026, 23:51 UTC

Gladstone Land Corp. shares rose in after-market trading, recovering from earlier losses amid broader market optimism following unchanged producer price index data.

13 août 2026, 23:51 UTC

L3Harris Technologies Inc. shares are higher in after-hours trading, reflecting positive market sentiment amid decreased expectations for a Federal Reserve interest rate hike.

13 août 2026, 23:51 UTC

StoneX Group Inc shares are lower in after-market hours, with no specific news identified. The asset remains near the lower end of its one-month trading range.

13 août 2026, 23:51 UTC

Asia equity markets show mixed performance as Japan's Nikkei rises on tech optimism and potential rate hikes, while China's Shanghai Composite dips amid geopolitical tensions and falling oil prices; U.S. jobless claims exceed expectations, softening inflation outlook.

13 août 2026, 23:51 UTC

Global equity markets rise, led by U.S. mega-caps, while mixed economic signals emerge from jobless claims and inflation data.

13 août 2026, 23:51 UTC

Mixed trading in European equities as UK GDP growth exceeds expectations while industrial production shows weakness amidst fluctuating oil prices and trade balance concerns.

13 août 2026, 23:51 UTC

U.S. equity indices remain flat as investors weigh mixed economic signals, rising jobless claims, and easing inflation amid geopolitical tensions and falling oil prices.

13 août 2026, 23:51 UTC

Australia's Westpac Consumer Confidence Report Set for August 18 Amidst Cautious Market Sentiment and Inflation Concerns.

13 août 2026, 23:51 UTC

Michigan Consumer Sentiment Report Set for August 14, Forecasted at 54.5 Amid Cautious Optimism Following Stable Inflation Data

13 août 2026, 23:51 UTC

US Business Inventories MoM data for June 2026 set to release on August 14, with a modest increase of 0.1% anticipated amid cautious market sentiment and inflation concerns.

13 août 2026, 23:51 UTC

Cautious Market Awaits July 2026 Building Permits Data Amid Ongoing Construction Sector Weakness and Rising Costs

13 août 2026, 23:51 UTC

NIO Inc shares are higher in after-market trading, reflecting broader market trends amid unchanged producer prices and reduced interest rate hike expectations.

13 août 2026, 23:51 UTC

Digital Realty Trust Inc shares are higher in after-market trading, reflecting broader market optimism following recent economic data and a recovery from earlier lows.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

109.97% hausse

Prévisions sur 12 Mois

Moyen 31.6 USD  109.97%

Haut 40 USD

Bas 27 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

5

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat